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We analyzed results of recent microbiologic surveil-
lance of meningitis in northern Cameroon. During the 2007 
and 2008 meningitis seasons, all 57 identiﬁ  ed  meningo-
coccal isolates were serogroup W135. This situation might 
indicate that the area is experiencing a period between 
epidemic waves due to 2 different clones of serogroup A 
meningococci. 
T
he 3 provinces constituting the Septentrion, in North 
Cameroon, belong to the so-called African meningitis 
belt (1). Until now, in these provinces, the diagnosis of men-
ingitis was made essentially on the basis of clinical signs, 
and biologic conﬁ  rmation was uncommon. The rare data 
that documented meningococci circulating in recent years 
in this area refer mostly to the early 1990s (2,3), when sero-
group A was by far the most frequently identiﬁ  ed serogroup 
in Cameroon, with strains having the antigenic formula 
A:4:P1.9 and belonging to the sequence type 5 (ST-5) com-
plex (4). From 1999 through 2001, a few cases of menin-
gitis were attributed to serogroup W135 (W135:2a:P1.5,2; 
ST-11), but these data were from Yaounde, in the southern 
part of the country (5).
The Study
In 2007, microbiologic surveillance of bacterial men-
ingitis was reintroduced in northern Cameroon to monitor 
the changing epidemiology of meningococci, with particu-
lar attention to uncommon serogroups, such as W135 or 
X, which have been unusually frequent in Sahelian Africa 
since 2000 (6–10). Health authorities decided that an ali-
quot of every cerebrospinal ﬂ  uid (CSF) specimen collected 
in this area would be sent to the Centre Pasteur du Cam-
eroun in Garoua (CPCAG) for testing. Laboratory proce-
dures included assessment of CSF turbidity, Gram staining, 
search for soluble capsular antigens by using the Pastorex 
(Bio-Rad, Hercules, CA, USA) latex agglutination kit and 
dipstick rapid diagnostic test for Neisseria meningitidis 
serogroups A, C, W135, and Y (kindly provided by the 
Centre de Recherche Médicale et Sanitaire, Niamey, Ni-
ger) (11). CSF specimens were cultured on blood agar and 
chocolate agar, supplemented with Polyvitex (bioMérieux, 
Marcy-l’Etoile, France), with incubation at 37°C with 5% 
CO2. Susceptibility to β-lactam antimicrobial drugs and 
chloramphenicol was tested according to the recommenda-
tions of the Antibiogram Committee of the French Society 
for Microbiology. The isolates of N. meningitidis were sent 
to the World Health Organization Collaborating Centre 
(WHOCC) for Reference and Research on Meningococci 
in Marseilles, France.
Overall, 409 CSF specimens were tested at CPCAG 
microbiology laboratory from January 1, 2007, through 
June 30, 2008, of which 144 (35.2%) had a leukocyte count 
evocative of bacterial meningitis. Online Appendix Figure 
1 (available from www.cdc.gov/EID/content/15/2/340-
appF1.htm) shows the monthly distribution of CSF speci-
mens tested at CPCAG.
The number of CSF specimens tested at CPCAG in-
creased greatly after 2006 as the number of health facili-
ties sending specimens for testing increased (Table). This 
rise was not related to any epidemic, but showed the inter-
est of healthcare workers in microbiologic surveillance of 
meningitis. The number of tested CSF specimens peaked 
in March and April, during the dry season, and was low 
during the rainy season (August and September). Overall, 
24 Streptococcus pneumoniae, 23 Haemophilus inﬂ  uenzae, 
and 57 N. meningitidis isolates were identiﬁ  ed, either from 
culture or by soluble antigens identiﬁ  cation.
S. pneumoniae and H. inﬂ  uenzae were identiﬁ  ed 
throughout the year, but N. meningitidis was observed 
only during the dry season, considered the classical men-
ingitis season in the African meningitis belt (1). The me-
dian ages of 11 patients with conﬁ  rmed S. pneumoniae 
infection and 11 patients with conﬁ  rmed H. inﬂ  uenzae 
infection were 14 and 0.6 years, respectively. Neither S. 
pneumoniae (12) nor H. inﬂ  uenzae isolates (8) were se-
rotyped. The median age of 43 patients with conﬁ  rmed 
meningococcal meningitis was 8 years (25th percentile 
4.8 years, 75th percentile 15.5 years).
Fifteen N. meningitidis isolates were recovered from 
culture, representing 28.3% of CSF specimens testing 
positive for soluble antigens. The frequent implementa-
tion of early presumptive treatment with antimicrobial 
drugs, as well as the unsuitable conditions for CSF speci-
mens transport from health facilities, might account for 
this low rate of positive cultures. The implementation of 
PCR for the diagnosis of N. meningitidis, S. pneumoniae, 
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and H. inﬂ  uenzae in CPCAG in Garoua in 2009 will enable 
further enhancement of the surveillance.
All diagnosed meningococci belonged to serogroup 
W135, although serogroup A has been classically the most 
prevalent in this Sahelian region, according to surveys car-
ried out in Garoua (2,3). N. meningitidis serogroup A seems 
to have completely disappeared since the renewal of the mi-
crobiologic surveillance of meningitis in northern Camer-
oon began in February 2007. To our knowledge, there was 
no previous report in the literature of such a predominance 
of serogroup W135 in countries of the meningitis belt. 
Nine of our 15 N. meningitidis isolates were genotyped 
by using multilocus sequence typing by the WHOCC in 
Marseille. Eight were identiﬁ  ed as ST-2881 and 1 as ST-
11. These ﬁ  ndings are consistent with the presence of only 
sporadic cases of serogroup W135 meningococcal menin-
gitis. Until now, ST-2881 has only been associated with 
sporadic cases or small epidemics, contrary to the ﬁ  nd-
ings for ST-11, which was involved in a large epidemic in 
Burkina Faso in 2002 (10,12).
We did not observe any resistance of N. meningitidis to 
β-lactam antimicrobial agents and chloramphenicol. These 
ﬁ  ndings did not question probabilistic treatment of suspect-
ed cases of meningococcal meningitis based on ceftriaxone 
or oily chloramphenicol in epidemic situations (13).
Laboratory-conﬁ  rmed cases of serogroup W135 menin-
gococcal meningitis were from Garoua and 9 other health 
facilities (online Appendix Figure 2, available from www.
cdc.gov/EID/content/15/2/340-appF2.htm). Most cases 
were from the North and Extreme North Provinces. Ad-
amaoua Province seemed to be less affected, likely because 
of climate and lower population density.
Our results differ clearly from those observed in 
Yaounde, the capital, which has a subequatorial climate. In 
1999–2000, S. pneumoniae was the main causative bacterial 
agent identiﬁ  ed in meningitis (109/194, 56%), followed by 
H. inﬂ  uenzae (36/194, 18.6%) and N. meningitidis (26/194, 
13.4%) (14).
WHO does not recommend systematic preventive vac-
cination with the bivalent A + C polysaccharide vaccine, 
but does recommend reactive mass immunizations of at-
risk populations when the epidemic threshold is crossed. 
This policy was applied in northern Cameroon in 1992, 
1993, 1996, and 1998, when >400,000 doses of vaccine 
were administered each year for epidemic control. After 
this period, 30,000–40,000 persons received preventive 
immunization against N. meningitidis serogroups A and C 
each year. However, the vaccination coverage is too low 
in this population of ≈6 million inhabitants to explain by 
itself the current absence of serogroup A meningococci in 
this area.
Conclusions
The renewal of microbiologic surveillance of meningi-
tis highlighted the fact that serogroup W135 was the only 
serogroup of N. meningitidis involved in endemic menin-
gitis cases in northern Cameroon in 2007 and 2008. Se-
rogroup A meningococci seemed to be completely absent 
during this period. This ﬁ  nding might reﬂ  ect the transitory 
period separating 2 epidemic waves caused by 2 different 
clones of serogroup A meningococci (15); the emergence of 
the next epidemic clone is thus possible at any moment. In 
the meantime, this situation has been considered by WHO, 
and vaccines that include protection against serogroup 
W135, such as trivalent vaccine (ACW135), are available 
for immunization campaigns to control epidemics. This 
vaccine is available in small quantities and can be deliv-
ered only by the International Coordinating Group (created 
in 1997 by WHO to distribute vaccine ACW135). WHO 
does not recommend this vaccine when meningococcal 
meningitis is endemic. Unless an epidemiologic upheaval 
occurs, future large epidemics of meningococcal meningi-
tis will likely be caused by serogroup A, and the serogroup 
A conjugate vaccine (which will soon be introduced in the 
meningitis belt) will be a major advance. However, its suc-
cessful implementation might create a favorable climate for 
other serogroups such as W135. In the future, a low-cost 
conjugate vaccine that includesW135 and perhaps X and Y 
serogroups can be anticipated.
In the early 2000s, scientists and WHO expressed fear 
of epidemics caused by serogroup W135 in countries of the 
African meningitis belt, but the epidemic in Burkina Faso 
remained isolated. Because the W135 serogroup ST-2881 
is known to be less epidemic than W135 ST-11, ST-2881 
could have replaced it in the ecologic niche and also have 
resulted in immunologic protection against ST-11. The 
observations made in northern Cameroon conﬁ  rm that we 
must continue to take into account serogroup W135 and 
that laboratories should be able to identify it routinely. 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 2, February 2009  341 
Table. CSF specimens from Cameroon tested at CPCAG laboratory in 2007 and 2008 and number of health facilities that sent 
specimens, compared with 2006 efforts* 
Characteristic 2006 2007 2008†
No. tested CSF specimens  60 202 207
Health facilities involved  Garoua Hospital  Garoua Hospital plus 8 other 
health facilities 
Garoua Hospital plus 17 other 
health facilities 
Specimens not collected in Garoua  0 27 79
*CSF, cerebrospinal fluid; CPCAG, Centre Pasteur du Cameroun in Garoua. 
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